SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)

Tuesday, April 10, 2018 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

JERSEY CITY, N.J., April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative

anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced three poster presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April
21-24, 2018
, in Madrid, Spain. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

Title: In Vitro Activity of SCY-078, a Novel IV/Oral Glucan Synthase Inhibitor, against Aspergillus spp., Alone or in Combination with other Antifungal TherapiesPresenter: Mahmoud Ghannoum PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO164Session: Aspergillus in the laboratory

Title: Activity of SCY-078 and comparators against a collection of Aspergillus spp. including cryptic species and Cyp51A mutantsPresenter: Ana Alastruey-Izquierdo PhDDate and Time: Saturday, April 21, from 15:30-16:30 CETPoster Presentation #: PO165Session: Aspergillus in the laboratory

Title: SCY-078 Demonstrates Antifungal Activity Against Pneumocystis in a Prophylactic Murine Model of Pneumocystis PneumoniaPresenter: Stephen Barat PhDDate and Time: Sunday, April 22, from 13:30-14:30 CETPoster Presentation #: P1226Session: Update on Pneumocystis

The ECCMID 2018 posters will be available on the SCYNEXIS website following the event.

About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

CONTACT:

Investor RelationsSusan KimArgot PartnersTel: 212-203-4433susan@argotpartners.com

Media RelationsGeorge E. MacDougallMacDougall Biomedical CommunicationsTel: 781-235-3093george@macbiocom.com

Cision View original content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-disease-eccmid-300625304.html

SOURCE SCYNEXIS, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store